WallStreetZenWallStreetZen

NASDAQ: CTMX
Cytomx Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CTMX

Based on 4 analysts offering 12 month price targets for Cytomx Therapeutics Inc.
Min Forecast
$3.50+204.35%
Avg Forecast
$5.77+402%
Max Forecast
$8.00+595.65%

Should I buy or sell CTMX stock?

Based on 4 analysts offering ratings for Cytomx Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTMX stock forecasts and price targets.

CTMX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-28
lockedlocked$00.00+00.00%2024-05-09
lockedlocked$00.00+00.00%2024-05-09
lockedlocked$00.00+00.00%2024-05-06

1 of 1

Forecast return on equity

Is CTMX forecast to generate an efficient return?

Forecast return on assets

Is CTMX forecast to generate an efficient return on assets?
Company
-29.44%
Industry
26.49%
CTMX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTMX earnings per share forecast

What is CTMX's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$0.29-308.57%
Avg 2 year Forecast
-$0.56-501.79%
Avg 3 year Forecast
-$0.57-504.79%

CTMX revenue forecast

What is CTMX's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$103.8M-13.15%
Avg 2 year Forecast
$84.1M-29.68%
Avg 3 year Forecast
$78.7M-34.15%
CTMX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTMX revenue growth forecast

How is CTMX forecast to perform vs Biotechnology companies and vs the US market?
Company
-14.35%
Industry
35.81%
Market
9.63%
CTMX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTMX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTMX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTMX$1.15$5.77+402.00%Strong Buy
ALVR$0.79N/AN/A
HOWL$2.03$13.50+565.02%Buy
ALXO$1.68$10.67+534.94%Buy
HLVX$1.77$7.75+337.85%Buy
View Top Biotech Stocks

Cytomx Therapeutics Stock Forecast FAQ

Is Cytomx Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CTMX) stock is to Strong Buy CTMX stock.

Out of 4 analysts, 2 (50%) are recommending CTMX as a Strong Buy, 1 (25%) are recommending CTMX as a Buy, 1 (25%) are recommending CTMX as a Hold, 0 (0%) are recommending CTMX as a Sell, and 0 (0%) are recommending CTMX as a Strong Sell.

If you're new to stock investing, here's how to buy Cytomx Therapeutics stock.

What is CTMX's earnings growth forecast for 2024-2026?

(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.7%.

Cytomx Therapeutics's earnings in 2024 is $11,086,000.On average, 5 Wall Street analysts forecast CTMX's earnings for 2024 to be -$22,810,339, with the lowest CTMX earnings forecast at -$38,277,624, and the highest CTMX earnings forecast at -$8,592,936. On average, 4 Wall Street analysts forecast CTMX's earnings for 2025 to be -$43,941,151, with the lowest CTMX earnings forecast at -$59,369,377, and the highest CTMX earnings forecast at -$35,934,096.

In 2026, CTMX is forecast to generate -$44,269,244 in earnings, with the lowest earnings forecast at -$48,432,913 and the highest earnings forecast at -$38,277,624.

What is CTMX's revenue growth forecast for 2024-2026?

(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -14.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.63%.

Cytomx Therapeutics's revenue in 2024 is $119,569,000.On average, 5 Wall Street analysts forecast CTMX's revenue for 2024 to be $8,112,356,629, with the lowest CTMX revenue forecast at $6,616,560,805, and the highest CTMX revenue forecast at $9,358,488,600. On average, 5 Wall Street analysts forecast CTMX's revenue for 2025 to be $6,568,049,774, with the lowest CTMX revenue forecast at $3,905,880,050, and the highest CTMX revenue forecast at $7,928,936,502.

In 2026, CTMX is forecast to generate $6,150,433,080 in revenue, with the lowest revenue forecast at $3,905,880,050 and the highest revenue forecast at $7,928,936,502.

What is CTMX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CTMX) forecast ROA is -29.44%, which is lower than the forecast US Biotechnology industry average of 26.49%.

What is CTMX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CTMX price target, the average CTMX price target is $5.77, with the highest CTMX stock price forecast at $8.00 and the lowest CTMX stock price forecast at $3.50.

On average, Wall Street analysts predict that Cytomx Therapeutics's share price could reach $5.77 by May 28, 2025. The average Cytomx Therapeutics stock price prediction forecasts a potential upside of 402% from the current CTMX share price of $1.15.

What is CTMX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CTMX) Cytomx Therapeutics's current Earnings Per Share (EPS) is $0.14. On average, analysts forecast that CTMX's EPS will be -$0.29 for 2024, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.11. On average, analysts forecast that CTMX's EPS will be -$0.56 for 2025, with the lowest EPS forecast at -$0.76, and the highest EPS forecast at -$0.46. In 2026, CTMX's EPS is forecast to hit -$0.57 (min: -$0.62, max: -$0.49).

What is CTMX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CTMX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.